About this study
This research study will test a new medicine called a bispecific antibody in children with acute myeloid leukemia (AML) that has come back (relapsed) or never went away despite chemotherapy (refractory). The name of the bispecific antibody is CD33xCD3. An antibody is a protein used by the immune system to find and destroy foreign molecules.
A bispecific antibody tries to bring parts of the immune system called T cells together with AML cells to help the T cells kill the leukemia cells. The antibody in this study targets a protein called CD33. This protein is found on most AML cells.
Scientists want to find the best dose of the antibody that can be safely given to children with relapsed or refractory AML. The researchers also want to learn more about how this antibody targets AML.
Eligibility overview
- Have relapsed or refractory AML
- Ages 2 to 21 years
- Weigh more than 24 lbs.